Innovate UK Grant awarded to Unitive Design & Analysis

Unitive Design & Analysis Ltd, a London-based SME, are delighted to announce their success in being awarded a grant by Innovate UK, the UK’s innovation agency.

Working with the University of Bristol, partners in the UK Quantum Technology Hub and part of the UK National Quantum Technologies Programme, this grant supports the development of a commercial direction for the Quantum Light Source (QLS) - an enormously exciting technology which has profound implications for the future of imaging applications.

QLS represents the successful culmination of research by the UofB who have  demonstrated imaging and sensing ‘beyond the shot noise limit’ using quantum technology. Supported by QuantIC and the Quantum Technology Enterprise Centre, Bristol’s research opens a paradigm shift,  providing a way to move beyond classical limitations of metrology which until now have been an inevitable part of all imaging and sensing.

The Bristol team reached out to Unitive Design and Analysis (UDA) as their chosen industry partner to help direct their research focus towards the needs of industry.

“We are proud to lead this incredibly exciting project and believe that the UK is poised to bring world-leading technology to imaging and sensing applications which will have a significant impact in industry”, Dr Phil Marsden, founder and Managing Director of Unitive Design, is adamant that finding real world applications is now the main challenge.

We’ll be engaging with innovators in industry and research to investigate ways that QLS can bring benefits by enabling faster, more accurate measurements and imaging, while reducing damage in organic and fragile materials. We’re calling on interested parties to get in touch”.

Dr Phil Marsden, Unitive Design

The QLS has the potential to be a UK-first, QT-based commercial enhanced imaging product. Ultimately the identification of relevant industrial sectors will ensure that new research on the QLS delivers the performance metrics and characteristics which will be key drivers for commercial adoption. Establishing the means to bring this future closer to a commercial reality is the focus of this innovative project.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New AI tool maps millions of CD8+ T cells to advance disease research